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Open Conversion after 
Aortic Endograft Infection
Caused by Colistin-Resistant, Carbapenemase-
Producing Klebsiella pneumoniae
A 62-year-old man presented with fever, abdominal pain, and malaise 13 months after 
emergency endovascular aortic repair. Computed tomographic angiograms showed a 
periprosthetic fluid and gas collection, so infection was diagnosed. Open conversion was 
performed, involving endograft explantation and in situ aortic reconstruction. Cultures and 
the explanted prosthesis were positive for carbapenemase-producing Klebsiella pneu-
moniae, resistant to colistin. Because of the sparse data on endograft infections caused 
by this pathogen, we placed the patient on an empiric double-carbapenem regimen for 
4 weeks. Symptomatic recovery occurred after 21 days. On the 30th day, we deployed 
a stent to treat a new pseudoaneurysm. Three years later, the patient had no signs of 
persistent or recurrent infection. We think that this is the first report of aortic endograft 
infection caused by colistin-resistant, carbapenemase-producing K. pneumoniae. (Tex 
Heart Inst J 2016;43(5):453-7)
E ndovascular aneurysm repair (EVAR) has become an alternative to aortic surgery and is often the treatment of choice for patients who have favorable anatomy.1-4 Results from EVAR can equal or exceed those of open surgery; 
however, EVAR’s higher complication rate necessitates monitoring, in case patients 
need reintervention.5,6 Although one of the least frequent causes of reintervention is 
infection (incidence, <1% of EVAR cases),7-9 it is associated with high mortality rates 
for surgically and conservatively treated patients.10-15 Bloodstream infections caused 
by carbapenemase-producing Klebsiella pneumoniae (CPKP) are typically associated 
with a mortality rate of 13% to 58%, and few therapeutic options are available.16,17
 We present what we think is the f irst case of aortic endograft infection caused 
by colistin-resistant CPKP, report the therapeutic regimen and surgical course in a 
62-year-old patient, and discuss the relevant medical literature.
Case Report
In September 2011, a 62-year-old man who had arterial hypertension, dyslipidemia, 
and paroxysmal atrial fibrillation was referred to a vascular center because of sudden-
onset lumbar pain and fever. The patient underwent urgent EVAR for an inflamma-
tory abdominal aortic aneurysm. A 31 × 14 × 145-mm Gore® Excluder® endograft 
(W.L. Gore & Associates, Inc.; Flagstaff, Ariz) was deployed.
 After EVAR, the patient’s lumbar pain promptly disappeared, but his fever persisted. 
Blood cultures grew methicillin-resistant Staphylococcus epidermidis, and a urine cul-
ture contained >100,000 colony-forming units of Pseudomonas aeruginosa and Serratia 
marcescens. Examination of the central venous catheter tip used during the EVAR pro-
cedure yielded Candida albicans. The patient underwent 50 days of specific antibiotic 
therapy until his fever disappeared, and then he was discharged from the hospital. 
During his hospitalization, a computed tomographic angiogram (CTA) showed thick-
ening and enhancement of the aortic wall, suggesting a persistent, intense periaortic 
inflammatory reaction.
 In November 2012, the patient was admitted to our hospital with fever (tem-
perature, 38.8 °C), abdominal pain, and malaise. Blood tests revealed mild anemia 
(hemoglobin, 10.7 g/dL), leukocytosis (white blood cell count, 18.25 ×109/L) with 
significant neutrophilia (neutrophils, 15.77 ×103/µL), an elevated serum C-reactive 
protein level of 27.95 mg/L, and an erythrocyte sedimentation rate of 56 mm/hr. 
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An emergency CTA showed a perigraft gas collection, 
consistent with endograft infection (Fig. 1).
 Even in the absence of melena, an esophagogastro-
duodenoscopy was performed, to exclude a secondary 
aortoenteric f istula. Surgical conversion consisting of 
endograft explantation and aortic reconstruction was 
planned.
 Surgery was performed through a median xifopubic 
laparotomy. The juxtarenal aortic wall was substantially 
inflamed, so suprarenal clamping was necessary. Renal 
hypothermia was achieved by selective perfusion of 
the renal arteries (4 °C lactated Ringer solution with 
12.5 g/L of mannitol and 125 mg/L of methylpred-
nisolone).18 The endograft (Fig. 2A) was completely 
removed, and infrarenal reconstruction was performed 
in end-to-end fashion with use of a rifampin-soaked, 
silver-coated Dacron bifurcated graft (Fig. 2B).
 During the patient’s 9-day postoperative intensive 
care unit stay, he had fever (temperature, 39 °C) and 
pneumonia. Blood cultures, bronchoalveolar-lavage 
fluid samples, and the explanted prosthesis were positive 
for colistin-resistant CPKP: the minimum inhibitory 
concentrations of ertapenem, meropenem, and colistin 
were 128, 256, and ≥16 µg/mL, respectively. In accor-
dance with the available medical literature,17 empiric 
therapy with fosfomycin (3 g, 4×/d) and tigecycline (50 
mg, 2×/d) was started; however, the fever and positive 
cultures persisted.
 An experimental protocol at our hospital enabled the 
intravenous administration of ertapenem (1 g/d) for 4 
weeks and meropenem (2 g, 3×/d). The patient’s fever 
completely resolved after 21 days of this regimen. On 
the 30th day, a CTA showed nothing unusual except a 
distal right anastomotic pseudoaneurysm (maximum 
diameter, 18 mm). We successfully treated the pseudo-
aneurysm by means of percutaneous endovascular relin-
ing, with use of an 11 × 90-mm Zenith® iliac leg (Cook 
Medical Inc.; Bloomington, Ind). The patient recovered 
uneventfully, had normal hematologic test results, and 
was discharged from the hospital 7 days postprocedur-
ally.
 Follow-up clinical examinations and laboratory tests 
were scheduled at 6 weeks; 3, 6, and 12 months; and 
annually thereafter. Monitoring with CTA was per-
formed at 6, 12, and 24 months. At the patient’s 3-year 
follow-up evaluation, he was in good clinical condition, 
Fig. 1  Preoperative computed tomographic angiogram shows 
periprosthetic fluid and gas collections associated with inflam-
mation of the aortic wall.
Fig. 2  Intraoperative photographs show A) evidence of graft 
infection and B) the completed reconstruction.
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with no laboratory or radiologic signs of persistent or 
recurrent infection (Fig. 3).
Discussion
The incidence of endograft infection after EVAR has 
been reported in major series as 0.2% to 0.9%,7,8,12-15 al-
though the actual rate is diff icult to estimate.19 Those 
percentages might rise, given the projected increases in 
numbers of EVAR procedures.
 The absence of a standardized follow-up protocol and 
the heterogeneous, nonspecific symptoms in the early 
phase of endograft infection can cause extensive delays 
in final diagnosis. Accordingly, at the time of treatment, 
patients often present in poor clinical condition and 
with a poor prognosis.19
 When open conversion is planned in these patients, 
high surgical risk is posed by their typically older age 
and poor clinical condition, by suprarenal or suprace-
liac aortic clamping, and by the technical challenges 
of endograft removal, especially in nonelective circum-
stances.12 The high mortality rates reported in all se-
ries thus far are of great concern. In one report, 16% of 
patients who underwent extra-anatomic reconstruction 
died, compared with 5.8% who had in situ reconstruc-
tion.7 For these reasons, less invasive treatments have 
been recommended for patients who have severe un-
derlying diseases.7-13 Results in those cases seem some-
what inferior to those in complete excision. Hart and 
colleagues20 found a 13% rate of recurrent infection in 
patients who underwent complete graft excision and a 
27% rate in those who underwent partial graft salvage. 
The postoperative mortality rates were 27% and 40% 
in the 2 treatment groups, respectively. These discour-
aging results are compounded by the lack of a specific 
and effective antibiotic therapy. In fact, microbiologic 
tests are negative in approximately 30% of cases, and a 
multibacterial cause has been reported in approximate-
ly 20% of endograft infections.21 Therefore, even after 
successful surgical endograft removal, concerns exist 
about proper antibiotic protocols. In accordance with 
accumulated knowledge about treating aortic-graft in-
fections,22-27 we chose to perform complete endograft 
excision and in situ aortic reconstruction in our patient.
 Microbiologic tests of our patient’s explanted endo-
graft revealed a very rare microorganism. Sepsis from 
CPKP is associated with a high mortality rate (13%–
58%).16,17 Results are even worse when colistin resistance 
is detected,28 because colistin is the core component of 
several therapeutic combinations.29 Patients who had 
sepsis caused by colistin-resistant CPKP had a signifi-
cantly higher mortality rate than did patients who had 
colistin-susceptible CPKP infections (40.6% vs 20.3%; 
P=0.04).28
 Some authors have reported successful results from 
a double-carbapenem regimen (ertapenem and either 
meropenem or doripenem).30-33 Ertapenem activity is 
greatly affected by carbapenemases, so it might act as 
a suicide substrate. After the carbapenemase receptors 
have been bound by ertapenem, the second carbapenem 
(meropenem or doripenem) can then exert its antimi-
crobial activity.31,34
 Because of the sparse data on endograft infections 
caused by colistin-resistant CPKP, we treated our pa-
tient with ertapenem and meropenem. The double-
carbapenem regimen induced a clinical response (initial 
defervescence), and a microbiologic response (no growth 
in blood cultures) 48 hours after antibiotic therapy was 
A
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Fig. 3  At the 3-year follow-up evaluation, computed tomo-
graphic angiograms show A) no evidence of recurrent infection 
(axial view), and B) good graft patency and correct positioning 
of the right iliac stent-graft (volume-rendered 3-dimensional 
reconstruction).
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started. Complete regression of symptoms occurred in 
21 days. The distal anastomotic pseudoaneurysm was 
detected during the scheduled 30-day CTA and was 
treated by deploying another endograft. Placing another 
graft in a recently infected anatomic f ield could have 
been hazardous, but we proceeded because the patient 
was judged to be clinically well and free from infection. 
The combined surgical removal of the endograft and 
the new pharmacologic treatment protocol provided a 
satisfactory result in our patient.
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